Synlait Denies a2 Milk and Fonterra Takeover Talks: Why Buying the Factory Was Never the Fix

a2 Milk sold 12.4% more product last year and made less money. Sales for the twelve months to 30 June 2026 reached NZ$1.98bn. Net profit fell 5.8% to NZ$207.5m. The gap sits inside one product line, in one quarter, at one factory the company does not own.

The same day those numbers landed, Synlait Milk filed a notice with the New Zealand exchange. It said it is not in talks with a2 Milk or Fonterra about any deal. Australian press had reported that the two might take Synlait private. a2 Milk said it does not comment on market talk. Fonterra said nothing.

Why the market reached for a takeover

The logic looked clean. a2 Milk owns 19.8% of Synlait. Synlait makes its China-label infant formula. In the fourth quarter a backlog at Synlait met slow customs clearance and extra product testing. Shelves in China ran empty. China-label infant formula sales fell 14% in a year when the rest of the range grew.

Buy the factory, the thinking goes, and you own the problem. That does not work here. Bright Dairy of Shanghai holds 65.25% of Synlait. a2 Milk cannot buy what its co-owner will not sell.

The rest of the year was strong

Take out China-label and the year reads well. Sales in China and other Asian markets rose 11.2% to NZ$1.45bn. Other nutrition lines in that region grew 71%. Australian liquid milk grew 17.2% to NZ$244.9m. US sales rose 28.6% to NZ$179m, and the US arm broke even in the second half.

The ordinary dividend rose 5% to 21 cents a share. a2 Milk added a special dividend of 41.4 cents. It then told the market that first-half profit in the new year will be well down, on flat sales. One bad quarter costs a full year.

The scarce asset is a licence

Here is the part most readers will have missed. China caps infant formula registrations at three per factory. Each one is a recipe a company is allowed to sell there. a2 Milk held one, and it sat inside Synlait.

In August 2025 a2 Milk paid NZ$282m for Yashili New Zealand Dairy and its plant at Pokeno. It added a NZ$100m upgrade on top. That deal came with two more China registrations. Buying Synlait would have added a plant a2 Milk used and a licence it held. The Yashili deal added the one thing money could not otherwise reach.

The plan now shows up in the guidance. a2 Milk is moving English-label a2 Platinum output into its own Pokeno site. It expects that site to break even next year. The company still says it wants to work with Synlait for the long term. It is also building a way to need it less.

Synlait had its own reasons

Synlait lost NZ$80.6m in the first half of its year. Net debt rose 88% to NZ$472.1m on sales of NZ$949m. Chief executive Richard Wyeth left in May after a year in the job. Its quality chief and its supply chain chief had gone before him.

Its shareholders have kept it going. Bright Dairy and a2 Milk backed a NZ$217.8m share issue. Bright Dairy also put in a NZ$130m loan. Synlait sold its North Island sites, including its own Pokeno plant, to Abbott for NZ$307m in April. Its banks want debt down to three times earnings by June 2027.

What buyers should take from this

Supply deals get priced as control questions. In regulated markets they are permission questions. Ask what the target holds that you cannot apply for, wait for or build. In infant formula that is a China registration. In drinks it can be a filling slot on one line. It can be a spring source consent, or a certificate with a two-year queue.

Owning a fifth of your supplier bought a2 Milk information and no control. The outage still happened. The fix was a second site with licences attached, bought a year before anyone needed it. Watch the a2 Milk annual meeting on 19 November for the recovery plan. Watch, too, whether Bright Dairy ever becomes a willing seller. Until it does, the takeover story stays a story.